$GRAL News

Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting

GRAIL (GRAL) Q2 2026 Earnings Call Transcript

GRAIL: Looking Beyond The NHS-Galleri Headline

FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test

Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date?

GRAIL Announces FDA Advisory Committee Meeting to Review Premarket Approval Application for the Galleri® Multi-Cancer Early Detection Test

GRAIL's Galleri Multi-Cancer Blood Test PMA Set For FDA Advisory Committee Review On Sept. 23

GRAIL, Inc. Q2 2026 Earnings Call Summary

GRAIL Inc (GRAL) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GRAIL Q2 Earnings Call Highlights

GRAIL, Inc. (GRAL) Q2 2026 Earnings Call Transcript

GRAIL Reports Second Quarter 2026 Financial Results

GRAIL Q2 EPS $(2.56) Beats $(2.62) Estimate, Sales $44.687M Beat $42.760M Estimate

GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference

GRAIL to Announce Second Quarter 2026 Financial Results

Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans

GRAIL Collaborates With Priority Health To Make GRAIL's Galleri Multi-Cancer Early Detection Test Available To Priority Health's Self-Insured Employer Groups

Mizuho Maintains Neutral on GRAIL, Raises Price Target to $65